Oral News and Research

RSS

RF-induced heat therapy could help treat common parasitic skin infection

Scientists are hoping that heat therapy could eventually replace a complex drug regimen as the first-line treatment of a parasitic skin infection common in tropical and subtropical regions of the world.

11 Feb 2011

Valeant Pharmaceuticals subsidiary acquires Canadian rights to Cholestagel

Valeant Pharmaceuticals International, Inc. today announced that its subsidiary, Biovail Laboratories International SRL, has acquired the Canadian rights to Cholestagel (colesevelam), an oral bile acid sequestrant for hypercholesterolemia, from Genzyme Corporation.

10 Feb 2011

FDA grants final approval for Hi-Tech Pharmacal's ANDA for levofloxacin ophthalmic solution

Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration granted final approval for the Company's Abbreviated New Drug Application for levofloxacin ophthalmic solution, 0.5% the generic for Vistakon's Quixin ophthalmic solution, which had sales of $2 million for the 12 months ended December 2010 according to IMS sales data.

10 Feb 2011

Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer. Tesetaxel, the leading oral taxane in clinical development, will be evaluated for its use as both first- and second-line chemotherapy.

10 Feb 2011

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

Zogenix, Inc. announced today the completion of enrollment in its pivotal Phase 3 efficacy study (Study 801) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.

10 Feb 2011

EMA grants QLT positive opinions for Orphan Drug Designation of QLT091001 to treat inherited blindness

QLT Inc. today announced that QLT091001, an oral synthetic retinoid, has received positive opinions for two distinct Orphan Drug Designations by the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) for the treatment of the inherited retinal degenerative diseases, Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).

10 Feb 2011

Vical 2010 net loss increases to $30.4 million

Vical Incorporated today reported financial results for the year ended December 31, 2010. Vical had cash and investments of approximately $61 million at year-end 2010. The company received approximately $37 million of net proceeds from the sale of equity securities during 2010.

10 Feb 2011

UCSD: Medication education can help patients with diabetes better stick to drug treatment plans

Researchers at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego say that medication education is a key factor in helping patients with diabetes better stick to their drug treatments plans.

10 Feb 2011

OraSure registers $3.5 million net loss for full year 2010

OraSure Technologies, Inc., a market leader in oral fluid diagnostics, today announced revenues of $75.0 million and $18.8 million for the year and quarter ended December 31, 2010, respectively. This compares to revenues of $77.0 million and $20.9 million for the year and quarter ended December 31, 2009.

10 Feb 2011

Opinions: Polio vaccines; Alternatives to DDT, insecticides; Food price volatility; Global poverty; Foreign aid for vaccines

"No one denies" that the oral polio vaccine "has considerable merits. It's cheap to make. It's easy to administer; you don't need a trained nurse with a clean syringe [like the inactive vaccine needs], just a volunteer with a dropper. And it gives excellent immunity. ... But there are problems with the method," Wendy Orent, author of the book Plague: The Mysterious Past and Terrifying Future of the World's Most Dangerous Disease, writes in a Los Angeles Times opinion piece.

10 Feb 2011

Cephalon to acquire Alba Therapeutics

Cephalon, Inc. and Alba Therapeutics Corporation, a privately held biopharmaceutical company, today announced that the companies have signed an agreement providing Cephalon with an option to purchase all of Alba's assets relating to larazotide acetate, a tight junction modulator, progressing toward a Phase IIb clinical trial for the treatment of celiac disease.

10 Feb 2011

Everolimus phase III study shows improved progression-free survival in patients with pNET

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin, has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Feb 2011

PBNC technology may help detect cardiac disease, reduce diagnostic costs

Heart disease is a silent killer, but new microchip technology from Rice University is expected to advance the art of diagnosis.

9 Feb 2011

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.

9 Feb 2011

Tulane surgeon performs new robotic-assisted surgery to treat head, neck cancers

Tulane University School of Medicine surgeon Dr. Paul Friedlander is performing a new, less-invasive form of robotic surgery to treat head and neck cancers.

9 Feb 2011

LESSOnc technique promising new surgical option for certain liver cancers

Surgeons at UC San Diego Health System have identified a new application for "scarless" surgery tools that are normally used for natural orifice translumenal endoscopic surgery (NOTES).

9 Feb 2011

Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI

Rib-X Pharmaceuticals, an antibiotics company with a broad development-stage pipeline, today announced the initiation of a Phase 2b clinical trial to evaluate delafloxacin, linezolid and vancomycin for the treatment of acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus.

8 Feb 2011

Oral News and Research

RF-induced heat therapy could help treat common parasitic skin infection

Valeant Pharmaceuticals subsidiary acquires Canadian rights to Cholestagel

FDA grants final approval for Hi-Tech Pharmacal's ANDA for levofloxacin ophthalmic solution

Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

EMA grants QLT positive opinions for Orphan Drug Designation of QLT091001 to treat inherited blindness

Vical 2010 net loss increases to $30.4 million

UCSD: Medication education can help patients with diabetes better stick to drug treatment plans

OraSure registers $3.5 million net loss for full year 2010

Opinions: Polio vaccines; Alternatives to DDT, insecticides; Food price volatility; Global poverty; Foreign aid for vaccines

Cephalon to acquire Alba Therapeutics

Everolimus phase III study shows improved progression-free survival in patients with pNET

PBNC technology may help detect cardiac disease, reduce diagnostic costs

Repligen third quarter total revenue increases 26% to $7,068,000

Tulane surgeon performs new robotic-assisted surgery to treat head, neck cancers

LESSOnc technique promising new surgical option for certain liver cancers

Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI

Anti-cancer shots for boys in the pipeline

Elan 2010 total revenue increases 5% to $1,169.7 million

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News